Document is current
Any future updates will be listed below
-
Authors
Wieske, Luuk
Kummer, Laura Y. L.
van Dam, Koos P. J.
Stalman, Eileen W.
van der Kooi, Anneke J.
Raaphorst, Joost
Löwenberg, Mark
Takkenberg, R. Bart
Volkers, Adriaan G.
D’Haens, Geert R. A. M.
Tas, Sander W.
Spuls, Phyllis I.
Bekkenk, Marcel W.
Musters, Annelie H.
Post, Nicoline F.
Bosma, Angela L.
Hilhorst, Marc L.
Vegting, Yosta
Bemelman, Frederike J.
Killestein, Joep
van Kempen, Zoé L. E.
Voskuyl, Alexandre E.
Broens, Bo
Sanchez, Agner Parra
Wolbink, Gertjan
Boekel, Laura
Rutgers, Abraham
de Leeuw, Karina
Horváth, Barbara
Verschuuren, Jan J. G. M.
Ruiter, Annabel M.
van Ouwerkerk, Lotte
van der Woude, Diane
Allaart, Cornelia F.
Teng, Y. K. Onno
van Paassen, Pieter
Busch, Matthias H.
Jallah, B. Papay
Brusse, Esther
van Doorn, Pieter A.
Baars, Adája E.
Hijnen, Dirkjan
Schreurs, Corine R. G.
van der Pol, W. Ludo
Goedee, H. Stephan
Steenhuis, Maurice
Rispens, Theo
ten Brinke, Anja
Verstegen, Niels J. M.
Zwinderman, Koos A. H.
van Ham, S. Marieke
Kuijpers, Taco W.
Eftimov, Filip
,
-
Funding
Funding for this research was provided by:
ZonMw (10430072010007)
- License Information
-
More Information
Article History
Received: 1 October 2021
Accepted: 21 February 2022
First Online: 2 March 2022
Declarations
:
: This study was approved by the medical ethical committee, and all participants provided signed informed consent (NL74974.018.20, EudraCT 2021-001102-30, Dutch Trial Register Trial ID: NL8900).
: Not applicable
: JV reported financial support from Target to B consortium, Prinses Beatrix Spierfonds, and has been involved in trials or consultancies for Argenx, Alexion, Rapharma. BH reported fees from Roche, Sanofi, Novartis and Janssen. JK reported speaking and consulting relationships with Biogen, Genzyme, Merck, Novartis, Roche, Sanofi and TEVA. AmsterdamUMC, location VUmc, MS Center Amsterdam, has received financial support for research activities from Biogen, Celgene, Genzyme, Merck, Novartis, Roche, Sanofi and TEVA. PS reported being involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of e.g. psoriasis and atopic dermatitis, for which financial compensation is paid to the department/hospital and is one of the main investigator of the TREAT registry taskforce and SECURE-AD registry. ML reported to have served as speaker and/or is a principal investigator for Abbvie, Alimentiv, Bristol Myers Squibb, Celgene, Covidien, Dr. Falk, Ferring Pharmaceuticals, Galapagos, Gilead, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Protagonist Therapeutics, Receptos, Takeda, Tillotts and Tramedico. FE, GW and TK reported a grant from ZonMW for COVID research in patients with auto-immune diseases. No other disclosures were reported.
